✦ LIBER ✦

710: Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting

✍ Scribed by Wang, J.; Lu, C.Y.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The genotyping of UGT1A1 polymorphism fo

✍ Lu, Chien-Yu; Tsai, Hsiang-Lin; Wang, Jaw-Yuan 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 169 KB

Prognostic advantage of irinotecan dose

✍ Lu, Chien-Yu; Huang, Ching-Wen; Hu, Huang-Ming; Tsai, Hsiang-Lin; Huang, Chun-Mi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 455 KB

UGT1A1 genotyping for irinotecan-based c

✍ Yeh, Yung-Sung; Wu, Ming-Xia; Huang, Meng-Lin; Chang, Se-Fen; Chen, Chin-Fan; Hu 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 185 KB

Evaluation in usual practice of the beva

✍ Metges, J. P.; Lebot, M. A.; Faroux, R.; Riaud, F.; Gamelin, E.; Capitain, O.; G 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 French ⚖ 233 KB